Evidence map›Paper›PMID 26835681›Full record

ArticleDiagnostics (Basel, Switzerland)2013

Overview of Five-Years of Experience Performing Non-Invasive Fetal Sex Assessment in Maternal Blood.

Sara Perlado-Marina, Ana Bustamante-Aragones, Laura Horcajada, Maria Jose Trujillo-Tiebas, Isabel Lorda-Sanchez, Marta Ruiz Ramos, Javier Plaza, Marta Rodriguez de Alba

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Non-invasive Prenatal Testing Using Fetal DNA.Molecular diagnosis & therapy · 2019
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sara Perlado-MarinaGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. sara.perlado@fjd.es.
Ana Bustamante-AragonesGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. abustamante@fjd.es.
Laura HorcajadaGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. laura.horcajada@fjd.es.
Maria Jose Trujillo-TiebasGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. mjtrujillo@fjd.es.
Isabel Lorda-SanchezGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. ilorda@fjd.es.
Marta Ruiz RamosGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. martaruizramos@hotmail.com.
Javier PlazaGynecology and Obstetric Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. jplaza@fjd.es.
Marta Rodriguez de AlbaGenetics Department, Fundacion Jimenez Diaz, Avda, Reyes Catolicos 2, Madrid 28040, Spain. mrodrigueza@fjd.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the discovery of the presence of fetal DNA in maternal blood, non-invasive fetal sex determination has been the test most widely translated into clinical practice. To date there is no agreement between the different laboratories performing such tests in relation to which is the best protocol. As a consequence there are almost as many protocols as laboratories offering the service, using different methodologies and thus obtaining different diagnostic accuracies. By the end of 2007, after a validation study performed in 316 maternal samples collected between the 5th and 12th week of gestation, the fetal sex determination was incorporated into clinical practice in our Service. The test is performed in the first trimester of pregnancy, and it is offered as part of the genetic counseling process for couples at risk of X-linked disorders. As a general rule and in order to avoid misdiagnosis, two samples at different gestational ages are tested per patient. The analysis is performed by the study of the SRY gene by RT-PCR. Two hundred and twenty six pregnancies have been tested so far in these 5 years. Neither false positives nor false negatives diagnoses have been registered, thus giving a diagnostic accuracy of 100%.

Indexed as

fetal DNAfetal sex determinationmaternal plasmanon-invasive prenatal diagnosis

Identifiers

PMID26835681
PMCPMC4665538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.